eMagin (AMEX:EMAN) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 40 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $7.21 million which missed the analyst consensus estimate of $8.00 million by 9.85 percent. This is a 6.12 percent decrease over sales of $7.68 million the same period last year.
Chardan Capital Maintains Buy on Achilles Therapeutics, Lowers Price Target to $17
Chardan Capital analyst Geulah Livshits maintains Achilles Therapeutics (NASDAQ:ACHL) with a Buy and lowers the price target from $20 to $17.
